Am­i­cus eyes Pompe ap­proval; Atea ends Dengue work; 2sev­en­ty, Tra­vere line up of­fer­ings

Am­i­cus Ther­a­peu­tics be­gan March with word that the FDA has sched­uled a pre-ap­proval in­spec­tion of its po­ten­tial treat­ment for Pompe dis­ease …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.